Topical corticosteroids in clinical practice: Focus on fluticasone propionate

Cutis

Volumn 57, Issue 2 SUPPL., 1996, Pages 4-9

  Piacquadio, Daniel J ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; ANTIINFLAMMATORY AGENT; FLUTICASONE; GLUCOCORTICOID;

HUMAN; REVIEW; SKIN DISEASE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; GLUCOCORTICOIDS; HUMANS; SKIN DISEASES;

EID: 0030078329     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Dermatology. Orkin M, Maibach HI, Dahl MV, eds. Appleton & Lange; Norwalk, CT: 1996:642-643.
2. Pariser DM. Topical steroids: a guide for use in the elderly patient. Geriatrics 1991;46:51-63.
3. Fusaro RM, Kingsley DN. Topical glucocorticoids. How they are used and misused. Postgrad Med 1986;79:283-291.
4. Young MMR, Sohail N, Harding SM. A comparison of the systemic absorption of fluticasone propionate and betamethasone valerate after topical application of cream formulations. Br J Derm 1994;131(suppl 44):35-36.
5. Cutivate Cream, 0.05% Product Monograph, April 1994.
6. Stoughton RB. Vasoconstrictor assay - specific applications. In: Maibach HI, Surber C, eds. Topical Corticosteroids. Basel, Switzerland: Karger; 1992:42-53.
7. Data on file, Glaxo Dermatology, Division of Glaxo Wellcome Inc.
8. Stoughton RB, Cornell RC. Corticosteroids. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al, eds. Dermatology in General Medicine. New York: McGraw-Hill, Inc. 1993:2846-2850.
9. Wolff ME. Structure-activity relationships in glucocorticoids. In: Baxter JD, Rousseau GG, eds. Glucocorticoid Hormone Action. Berlin, Germany: Springer-Verlag; 1979:97-107.
10. Ballard PL. Delivery and transport of glucocorticoids to target cells. In: Baxter JD, Rousseau GG, eds. Glucocorticoid Hormone Action. Berlin, Germany: Springer-Verlag; 1979:25-48.
11. Phillipps GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990; 84(suppl A):19-23.
12. Long CC, Finlay AY. The finger-tip unit - a new practical measure. Clin Exper Dermatol 1991;16:444-447.
13. Moschella SL, Hurley HJ. Dermatology. Philadelphia: W.B. Saunders Company; 1992:1849.
14. Long CC, Finlay AY, Averill RW. The rule of hand: 4 hand areas = 2 FTU = 1 g. Arch Dermatol 1992;128:1129-1130. Letter.
15. Stoughton RB, Wullich K. The same glucocorticoid in brand-name products. Does increasing the concentration result in greater topical biologic activity? Arch Dermatol 1989;125:1509-1511.
16. Hadzija BW, Ambrose WW. Comparison of cosmetic and physicochemical properties of six topical corticosteroid creams. Cutis 1996; 57(Suppl 2S):13-18.
17. Callen J. Comparison of safety and efficacy of fluticasone propionate cream, 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of moderate-to-severe psoriasis. Cutis 1996;57(Suppl 2S:) 45-50.
18. Nurnberger FG. A comparison of fluticasone propionate ointment, 0.005%, and hydrocortisone-17-butyrate ointment, 0.1%, in the treatment of psoriasis. Cutis 1996;57(Suppl 2S):39-44.
19. Roberts DT. Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis. Cutis 1996;57(Suppl 2S):27-31.